Tonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This draft policy governs coverage and coding for tonic motor activation (TOMAC), a bilateral peroneal nerve stimulation device for adults with primary moderate-to-severe restless legs syndrome (RLS) refractory to medication, and applies to Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage determinations and policy stance
Coverage determinations
From Medicare Advantage section
From Commercial Products section
Clinical pathway description
The following CPT/HCPCS codes are identified for billing and adjudication purposes: A4544 — Electrode for external lower extremity nerve stimulator for restless legs syndrome; and E0743 — External lower extremity nerve stimulator for restless legs syndrome, each. These codes are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products under this policy.
Services determined to be not medically necessary or otherwise non-covered may result in member financial responsibility. Providers may not charge the member for services that are non-covered or deemed not medically necessary unless the member has been informed and has agreed in writing in advance to assume financial responsibility. For member-specific benefits and eligibility, contact the provider call center and refer to the member’s subscriber agreement or employer agreement, which supersede this policy.
For Commercial Products, tonic motor activation (TOMAC) as a treatment for restless legs syndrome refractory to medication is considered not medically necessary because the evidence is insufficient to demonstrate an improvement in net health outcome.
Coding and billing guidance
Provider responsibilities, prior auth, and billing risk
Prior authorization: Not applicable — codes identified as not covered
Prior authorization does not apply to this draft policy; however, the policy identifies CPT/HCPCS codes A4544 and E0743 as not covered or not medically necessary and these codes should be used when adjudicating claims.
Verify benefits and eligibility via provider call center
Verify member benefits and eligibility with the provider call center before providing services; this policy does not guarantee payment and benefits are determined by the member's subscriber or employer agreement.
- Contact the provider call center for member-specific benefits and eligibility
- Member subscriber/employer agreement supersedes this policy
Therapy sequencing: TOMAC is not first-line — use after pharmacologic therapy
TOMAC is not a first-line therapy and should be considered only for moderate-to-severe primary RLS that is refractory to pharmacologic treatment after first-line therapies such as iron supplementation, gabapentinoids, and lifestyle modifications.
- Indicated for moderate-to-severe primary RLS refractory to medication
- First-line therapies include iron repletion, gabapentinoids, and lifestyle changes
Step therapy: Not specified
No step therapy requirements are specified in this policy.
- The document does not define a required sequence of prior authorization steps or mandatory medication trials beyond stating TOMAC is not first-line.
Benefits vary by group/contract — refer to EOC or Subscriber Agreement
Benefits and coverage may vary by group or contract; refer to the member's Evidence of Coverage or Subscriber Agreement for applicable coverage specifics.
- Policy is informational and not a guarantee of payment
- Use Evidence of Coverage/Subscriber Agreement to determine not medically necessary benefits
Call provider call center for member-specific benefits
For member-specific benefits and eligibility, providers must call the provider call center and rely on the member's subscriber or employer agreement, which supersede the policy.
- Call provider call center for member-specific information
- Subscriber/employer agreement governs benefits and eligibility
Denial risk: TOMAC claims (A4544, E0743) may be denied as not covered/not medically necessary
Claims for TOMAC, including services billed with CPT/HCPCS codes A4544 and E0743, are subject to denial as not covered for Medicare Advantage or not medically necessary for Commercial Products because evidence is insufficient to demonstrate improved net health outcome.
Member financial responsibility risk for non-covered or not medically necessary services
If services are determined to be not medically necessary or non-covered benefits, the provider may not charge the member unless the member was informed and agreed in writing in advance, which creates financial risk to the provider if not handled properly.
- Do not bill the member for non-covered/not medically necessary services unless there is a prior written agreement
- Refer to participation agreement provisions for billing rules
Clinical background
Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs and uncomfortable sensations that typically worsen at rest and during the evening or night, frequently disrupting sleep and often associated with periodic limb movements during sleep. First-line management includes addressing reversible contributors such as iron deficiency, implementing lifestyle modifications, and use of established pharmacologic therapies (for example, gabapentinoids and dopaminergic agents). Tonic motor activation (TOMAC) is a noninvasive neuromodulation approach that uses bilateral peroneal nerve stimulation via electrodes on the lower legs to activate the tibialis anterior muscles, producing sustained low-level contractions intended to mimic movement and reduce RLS symptoms. TOMAC is described as a non–first-line option for moderate-to-severe primary RLS that is refractory to pharmacologic therapy.
Key definitions used in this policy
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.